Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA7 | P43166 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 9/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.36 |
| ▸ | APLNR | P35414 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6611508 | 0.89 | CTSK (0.41) | CA1CA7CA12CA14TDP1 | |
| SCHEMBL10744068 | 0.87 | CTSK (0.40) | CA1CA7CA12CA14TDP1 | |
| SCHEMBL15824368 | 0.85 | TDP1 (0.41) | CA1CA7CA12CA14TDP1 | |
| SCHEMBL16929983 | 0.85 | TDP1 (0.41) | CA1CA7CA12CA14TDP1 | |
| SCHEMBL166623 | 0.85 | CA1 (0.42) | CA1CA7CA12CA14TDP1 | |
| SCHEMBL6610938 | 0.81 | CTSK (0.38) | CA1CA7CA12CA14TDP1 | |
| SCHEMBL10776406 | 0.81 | CA1 (0.40) | CA1CA7CA12CA14TDP1 | |
| SCHEMBL10100401 | 0.81 | CA1 (0.40) | CA1CA7CA12CA14TDP1 | |
| SCHEMBL6610088 | 0.81 | CTSK (0.38) | CA1CA7CA12CA14TDP1 | |
| SCHEMBL7881938 | 0.79 | MAOA (0.41) | CA1CA7CA12CA14TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210130315-A1 | METHOD FOR THE SYNTHESIS OF CYCLIC DEPSIPEPTIDES | BAYER ANIMAL HEALTH GMBH (DE) | 2021-05-06 | — | — | US | claimed |
| CN-111757880-A | Method for synthesizing cyclic depsipeptides | 拜耳动物保健有限责任公司 | 2020-10-09 | — | — | CN | claimed |
| EP-3676265-A1 | METHOD FOR THE SYNTHESIS OF CYCLIC DEPSIPEPTIDES | Bayer Animal Health GmbH (DE) | 2020-07-08 | — | — | EP | claimed |
| EP-3480195-A1 | METHOD FOR THE SYNTHESIS OF CYCLIC DEPSIPEPTIDES | Bayer Animal Health GmbH (DE) | 2019-05-08 | — | — | EP | claimed |
| US-7834007-B2 | CGRP antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-11-16 | — | — | US | claimed |
| US-20070049577-A1 | CGRP antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2007-03-01 | — | — | US | claimed |
| US-5856324-A | Use of dioxomorpholines for combat endoparasites, dioxomorpholines and process for their production | BAYER AKTIENGESELLSCHAFT (DE) | 1999-01-05 | — | — | US | claimed |
| US-5571793-A | COMBATTING ENDOPARASITES IN HUMANS OR ANIMALS BY ADMINISTERING PEPTIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1996-11-05 | — | — | US | claimed |
| EP-3383378-B1 | METHODS FOR INHIBITING CONVERSION OF CHOLINE TO TRIMETHYLAMINE (TMA) | PROCTER & GAMBLE (US) | 2024-04-17 | — | — | EP | disclosed |
| US-11780841-B2 | 3,6-methano-1H-pyrrolo[3,2-b]pyridine and 3,6-methano-1H-pyrrolo[3,2-c]pyridine compounds and medicaments using same | IRIMAJIRI THERAPEUTICS INC. (JP) | 2023-10-10 | — | — | US | disclosed |
| CN-116348147-A | Compositions for delivery of payload molecules to airway epithelium | 摩登纳特斯有限公司 | 2023-06-27 | — | — | CN | disclosed |
| EP-4104902-A1 | COMPOUND AND DRUG CONTAINING SAME | Oita University Institute of Advanced Medicine, Inc. (JP) | 2022-12-21 | — | — | EP | disclosed |
| US-20220194942-A1 | 3,6-METHANO-1H-PYRROLO[3,2-b]PYRIDINE AND 3,6-METHANO-1H-PYRROLO[3,2-c]PYRIDINE COMPOUNDS AND MEDICAMENTS USING SAME | IRIMAJIRI THERAPEUTICS INC. (JP) | 2022-06-23 | — | — | US | disclosed |
| US-20210214356-A1 | COMPOUNDS AND MEDICAMENTS USING SAME | IRIMAJIRI THERAPEUTICS INC. (JP) | 2021-07-15 | — | — | US | disclosed |
| EP-0662326-A2 | Endoparasitical agents containing praziquantel and epsiprantel | BAYER AG (DE) | 1995-07-12 | — | — | EP | disclosed |
| EP-0657172-A1 | Endoparasiticide drugs on a basis of open chain tetradepsipeptides | BAYER AG (DE) | 1995-06-14 | — | — | EP | disclosed |
| EP-0657173-A1 | Endoparasiticide drugs on a basis of open chain hexadepsipeptides | BAYER AG (DE) | 1995-06-14 | — | — | EP | disclosed |
| EP-0657171-A1 | Endoparasiticide drugs on a basis of open chain octadepsipeptides | BAYER AG (DE) | 1995-06-14 | — | — | EP | disclosed |
| EP-0423943-A2 | Use of collagenase inhibitors in the treatment of demyelinating diseases, in particular multiple sclerosis | Beecham Group p.l.c. (GB) | 1991-04-24 | — | — | EP | disclosed |
| US-4698337-A | Cephem compounds and processes for preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1987-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210130315-A1 | METHOD FOR THE SYNTHESIS OF CYCLIC DEPSIPEPTIDES | DNPEP, NPEPPS, PREP | CA1 2176/4885CA7 846/4885CA12 565/4885 |
| US-11780841-B2 | 3,6-methano-1H-pyrrolo[3,2-b]pyridine and 3,6-methano-1H-pyrrolo[3,2-c]pyridine compounds and medicaments using same | AVPR1B, AVPR2, F12 | CA1 773/4885CA7 906/4885CA12 661/4885 |
| US-20070049577-A1 | CGRP antagonists | CALCRL, CALCR, CALCA | CA1 2299/4885CA7 2237/4885CA12 2597/4885 |
| US-20210214356-A1 | COMPOUNDS AND MEDICAMENTS USING SAME | F12, GDI2, RDX | CA1 164/4885CA7 184/4885CA12 87/4885 |
| US-20220194942-A1 | 3,6-METHANO-1H-PYRROLO[3,2-b]PYRIDINE AND 3,6-METHANO-1H-PYRROLO[3,2-c]PYRIDINE COMPOUNDS AND MEDICAMENTS USING SAME | AVPR1B, AVPR2, F12 | CA1 773/4885CA7 906/4885CA12 661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.